Sleep Disorder Global Market Report 2026

Sleep disorders refer to a range of conditions that interfere with the body's normal sleep patterns, affecting the ability to fall asleep, remain asleep, or obtain restful sleep. These disorders may arise from physiological, neurological, or behavioral factors that disrupt healthy sleep cycles. They commonly result in reduced daytime functioning, impaired concentration, and adverse effects on overall well-being.

The primary disorder types of sleep disorder management include insomnia, sleep apnea, restless legs syndrome, narcolepsy, and circadian rhythm disorders. Insomnia refers to difficulty falling asleep, staying asleep, or achieving restorative sleep, often requiring targeted interventions to improve sleep quality and overall health. Treatment options include cognitive behavioral therapy, medication therapy, psychiatric treatment, and behavioral treatment. Diagnostic methods include polysomnography, home sleep testing, actigraphy, sleep diaries, and questionnaires or screening. Distribution occurs through retail pharmacies, online sales, and hospital pharmacies, and the key end users include hospitals and sleep centers, home care settings, and academic and research institutes.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs have moderately impacted the sleep disorder market by increasing costs for imported diagnostic devices, monitoring equipment, and medical electronics used in sleep testing and treatment. hospital sleep centers and home sleep testing segments are most affected, particularly in regions such as north america, europe, and asia-pacific where cross-border sourcing is common. higher costs have slowed procurement cycles for advanced sleep diagnostics. however, tariffs have encouraged regional manufacturing, local supplier development, and innovation in cost-effective sleep monitoring solutions, supporting long-term market stability.

The sleep disorder market research report is one of a series of new reports from The Business Research Company that provides sleep disorder market statistics, including sleep disorder industry global market size, regional shares, competitors with a sleep disorder market share, detailed sleep disorder market segments, market trends and opportunities, and any further data you may need to thrive in the sleep disorder industry. This sleep disorder market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The sleep disorder market size has grown rapidly in recent years. It will grow from $33.32 billion in 2025 to $38.23 billion in 2026 at a compound annual growth rate (CAGR) of 14.7%. The growth in the historic period can be attributed to increasing awareness about sleep health, rising prevalence of insomnia and sleep apnea, growing adoption of sleep diagnostic services, increasing geriatric population, rising stress and lifestyle-related sleep issues, growing smartphone and wearable device usage for sleep tracking.

The sleep disorder market size is expected to see rapid growth in the next few years. It will grow to $65.51 billion in 2030 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to expansion of telemedicine services for sleep disorders, rising adoption of wearable sleep trackers, increasing home-based diagnostic testing, growth of cognitive behavioral therapy applications, rising government initiatives on sleep health awareness. Major trends in the forecast period include advancement in wearable sleep monitoring devices, advancement in home-based sleep diagnostic tools, advancement in AI-driven sleep analysis, innovation in non-invasive therapies for sleep apnea, innovation in telemedicine for sleep consultation, innovation in cognitive behavioral therapy apps.

The rising levels of stress and anxiety are expected to propel the growth of the sleep disorder market going forward. Stress and anxiety levels refer to the widespread experience of psychological strain and persistent worry within a population, often arising from environmental, social, or economic pressures. These levels are increasing largely due to work-related challenges, as individuals face heavier workloads, strict deadlines, and growing job insecurity. Elevated stress and anxiety contribute to sleep disorders by disrupting normal sleep patterns and making it harder to fall asleep or maintain uninterrupted sleep. They also negatively affect overall health by reducing restorative sleep, leading to fatigue, diminished cognitive function, and a higher risk of chronic health conditions. For instance, in May 2024, according to the American Psychiatric Association (APA), a US-based professional association, 43% of U.S. adults reported feeling more anxious in 2024 than in the previous year, up from 37% in 2023 and 32% in 2022. Therefore, increasing stress and anxiety levels are driving the growth of the sleep disorder market.

Major companies operating in the sleep disorder market are focusing on developing advanced therapeutic technologies, such as electrical vestibular nerve stimulation (VeNS) methods, to provide non-drug treatment options that improve sleep quality, regulate circadian rhythms, and support patients with chronic insomnia. Electrical vestibular nerve stimulation (VeNS) refers to a non-invasive therapeutic approach that delivers low-level electrical pulses to the vestibular nerve, a key neural pathway that influences brain regions involved in sleep regulation, without the need for surgical intervention or pharmaceuticals. For instance, in October 2024, Neurovalens Ltd., a UK-based health-tech company, launched Modius Sleep, an FDA-cleared, non-invasive device designed to treat chronic insomnia using VeNS technology. The headset-style medical device is worn for approximately 30 minutes each evening and delivers safe electrical pulses to the vestibular nerve, targeting the hypothalamus and brainstem regions responsible for circadian rhythm and sleep regulation, thereby helping users fall asleep faster and maintain longer, more consistent sleep.

In July 2023, ResMed Inc., a US-based provider of sleep and respiratory care solutions, acquired Somnoware Healthcare Systems Inc. for an undisclosed amount. Through this acquisition, ResMed expanded its digital health and diagnostic capabilities by integrating Somnoware's software to strengthen sleep disorder diagnosis, workflow efficiency, and patient management across clinics and sleep laboratories. Somnoware Healthcare Systems Inc. is a US-based healthcare software company that specializes in solutions for sleep disorder diagnosis and care management.

Major companies operating in the sleep disorder market are Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Sanofi S.A., GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Biogen Inc., Union Chimique Belge S.A., Sun Pharmaceutical Industries Ltd., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Limited, H. Lundbeck A/S, Sumitomo Pharma Co. Ltd., Neurocrine Biosciences Inc., Harmony Biosciences Holdings Inc., Vanda Pharmaceuticals Inc.

North America was the largest region in the sleep disorder market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sleep disorder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the sleep disorder market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sleep disorder market consists of revenues earned by entities through sleep clinics, diagnostic sleep studies (polysomnography), cognitive and behavioral sleep therapy, sleep consultation, and monitoring services for sleep-related conditions. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Sleep Disorder Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses sleep disorder market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for sleep disorder ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The sleep disorder market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Disorder Type: Insomnia; Sleep Apnea; Restless Legs Syndrome; Narcolepsy; Circadian Rhythm Disorders
• 2) By Treatment: Cognitive Behavioral Therapy; Medication Therapy; Psychiatric Treatment; Behavioral Treatment
• 3) By Diagnostic Method: Polysomnography; Home Sleep Testing; Actigraphy; Sleep Diaries; Questionnaires and Screening
• 4) By Distribution Channel: Retail Pharmacies; Online Sales; Hospital Pharmacies
• 5) By End-User: Hospitals And Sleep Centers; Home Care Settings; Academic
• Subsegments:
• 1) By Insomnia: Acute Insomnia; Chronic Insomnia; Onset Insomnia; Maintenance Insomnia; Behavioral Insomnia; Medication-Induced Insomnia
• 2) By Sleep Apnea: Obstructive Sleep Apnea; Central Sleep Apnea; Complex Sleep Apnea Syndrome; Mild Sleep Apnea; Moderate Sleep Apnea; Severe Sleep Apnea; Pediatric Sleep Apnea; Treatment-Resistant Sleep Apnea
• 3) By Restless Legs Syndrome: Primary Restless Legs Syndrome; Secondary Restless Legs Syndrome; Mild Restless Legs Syndrome; Moderate Restless Legs Syndrome; Severe Restless Legs Syndrome; Intermittent Restless Legs Syndrome; Chronic Persistent Restless Legs Syndrome
• 4) By Narcolepsy: Narcolepsy Type 1; Narcolepsy Type 2; Idiopathic Hypersomnia; Pediatric Narcolepsy; Treatment-Resistant Narcolepsy; Secondary Narcolepsy
• 5) By Circadian Rhythm Disorders: Delayed Sleep Phase Disorder; Advanced Sleep Phase Disorder; Shift Work Sleep Disorder; Jet Lag Disorder; Irregular Sleep-Wake Rhythm Disorder; Non-24-Hour Sleep-Wake Disorder
• Companies Mentioned: Johnson & Johnson; Merck & Co. Inc.; Pfizer Inc.; Sanofi S.A.; GlaxoSmithKline plc; Eli Lilly and Company; Takeda Pharmaceutical Company Limited; Teva Pharmaceutical Industries Ltd.; Otsuka Holdings Co. Ltd.; Biogen Inc.; Union Chimique Belge S.A.; Sun Pharmaceutical Industries Ltd.; Eisai Co. Ltd.; Jazz Pharmaceuticals plc; Aurobindo Pharma Ltd.; Dr. Reddy's Laboratories Limited; H. Lundbeck A/S; Sumitomo Pharma Co. Ltd.; Neurocrine Biosciences Inc.; Harmony Biosciences Holdings Inc.; Vanda Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.